BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Displaced Palestinian families suffer as heavy rains flood Gaza tent camps - 2Grasping Wrongdoings and Crimes: A Correlation
- 3Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- 4Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- 5The hunt for dark matter: a trivia quiz
- Shrewd Home Gadgets to Save Energy
- A definitive Manual for Good dieting on a Tight spending plan
- Asia's Noteworthy Destinations: A Voyager's Aide
- Manual for Instructive Application for Youngsters
- Figure out How to Back Your Rooftop Substitution
- 6 Financial plan 3D Printers with the Best Worth
- The Best Traditional Music Arrangers in History
- 5 Signs Now is the ideal time to Update Your Android Telephone: When to Take the Action
- Instructions to Utilize Your Brain science Certification to Work on Corporate Culture
